J Neuroimmunol. 2003 Jun;139(1-2):150-4
Batocchi AP, Rotondi M, Caggiula M, Frisullo G, Odoardi F, Nociti V, Carella C, Tonali PA, Mirabella M.
Institute of Neurology, Catholic University, Largo Gemelli 8, 00168, Rome, Italy
The role of leptin was investigated in relapsing-remitting multiple sclerosis (MS).
Control and MS patients showed comparable baseline serum leptin levels.
During the first year of IFNbeta-1a treatment, leptin significantly decreased since 2 months after starting therapy in 11 patients who had no relapses.
A significant decrease in IL12/IL10 ratio was observed in this group of patients only after 1 year of treatment.
An increase of leptin was observed before the first clinical exacerbation in 13 relapsing patients.
Leptin may play a pathogenic role in MS and can be a useful marker of disease activity and response to therapy.